Key result
IV ketanserin abruptly lowers LVSP by ~17 mm Hg during cardiac catheterization.
Why the study?
Does an acute intravenous bolus of 10 mg ketanserin alter left ventricular function, metabolism, and coronary blood flow in patients undergoing cardiac catheterisation for chest pains?
Population
n=10 patients undergoing cardiac catheterisation for chest pains
Design
Case_series
Follow-up
acute
Authors
Loading...
Acute ketanserin may reduce LV systolic pressure without metabolic changes; leaves open effects in chronic use or broader populations.
Does an acute intravenous bolus of 10 mg ketanserin alter left ventricular function, metabolism, and coronary blood flow in patients undergoing cardiac catheterisation for chest pains?
Mean Difference: -17
p-value: p=<0.025
Acute intravenous ketanserin produces a non-specific hypotensive effect by lowering left ventricular systolic and pulmonary artery diastolic pressures without altering myocardial metabolism.
Walker et al. (1984) studied Chest pains (n=10). Ketanserin was evaluated on Left ventricular systolic pressure (fall of 17 ± 9.2 mm Hg, p=<0.025). An acute intravenous bolus of 10 mg ketanserin caused an abrupt fall in left ventricular systolic pressure of 17 ± 9.2 mm Hg (P<0.025) in patients undergoing cardiac catheterisation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: